As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
16 Analysts have issued a Capricor Therapeutics, Inc. forecast:
16 Analysts have issued a Capricor Therapeutics, Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 13 13 |
51%
51%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -73 -73 |
153%
153%
|
EBIT (Operating Income) EBIT | -73 -73 |
145%
145%
|
Net Profit | -70 -70 |
150%
150%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
Head office | United States |
CEO | Linda Marbán |
Employees | 160 |
Founded | 1996 |
Website | capricor.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.